Thomas D. Pollard

Thrive Bioscience Debuts Advanced Live Cell Imaging Software, Solving Major Problems in Cell-Based Research and Medicine

Retrieved on: 
Tuesday, December 19, 2023
Organoid, Documentation, Gene editing, Software, Research, Cell, B cell, CRISPR, Society, Thomas D. Pollard, 3D, DIC, Cell biology, Therapy, QPI, Medical imaging

BOSTON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Thrive Bioscience Inc., a provider of innovative automated live cell imaging instruments and software, debuted its CellAssist Software Release 5.0, a new integrated suite of advanced live cell imaging capabilities in December at Cell Bio 2023, the annual meeting of the American Society for Cell Biology.

Key Points: 
  • BOSTON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Thrive Bioscience Inc., a provider of innovative automated live cell imaging instruments and software, debuted its CellAssist Software Release 5.0, a new integrated suite of advanced live cell imaging capabilities in December at Cell Bio 2023, the annual meeting of the American Society for Cell Biology.
  • CellAssist Release 5.0 will be launched in mid-2024 with Beta versions of the software available now to collaborators and customers.
  • Thrive’s implementation of QPI, combined with proprietary algorithms, enables Thrive's superior cell counting, confluence measuring, and computed DIC imaging.
  • “Thrive CellAssist instruments have solved major gaps in cell biology with its groundbreaking accuracy in counting cells and determining their confluence, measurements that are fundamental to cell-based research and therapeutics.

Newtown's Apple to Highly Saturated Global Molecular Market, TIANGEN TGuide S16 Automated Nucleic Acid Extractor Showcased at Cell Bio 2022

Retrieved on: 
Tuesday, December 6, 2022
Duke University, Cell biology, Thomas D. Pollard, Society, Research, ASCB, Cell, S16, University of California, Molecular biology, Wizard Product Review, EMBO, University, GM, European Molecular Biology Organization, Harvard Medical School, RNA, Fine chemical, A4

Eye-catching as it is, the smart automated extractor hit the great potential need of global research scientists about nucleic acid purification and received more than 50 direct trial requests.

Key Points: 
  • Eye-catching as it is, the smart automated extractor hit the great potential need of global research scientists about nucleic acid purification and received more than 50 direct trial requests.
  • For molecular and cell biologists, nucleic acid purification column kits are highly redundant in the global molecular market.
  • Serving these demands, TIANGEN designed the groundbreaking research oriented automated extractor: the TGuide S16, empowered by insights of scientist behaviors and expectations, the 12-year experience on automated extractors, and rich supporting reagent kit pools.
  • It has been committed to providing customers with a total solution from sample storage to nucleic acid extraction and detection.

bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting

Retrieved on: 
Thursday, December 1, 2022
Research, Surgery, Medical Devices, Genetics, Biotechnology, Radiology, Health, Science, Oncology, Marketing, EST, Thomas D. Pollard, European Molecular Biology Organization, Laboratory, Lung, Gene, CD320, Brain, ASCB, University of Texas Southwestern Medical Center, University, Cell biology, Prostate, Society, Laboratory developed test, Sirna Therapeutics, LDT, EMBO, Therapy, Cell, Walter, LRP2, BIAF, Biology, Breast, Medical imaging, Research, D.C

Dr. Elzis recent research that will be presented next week at Cell Bio looks at why it works.

Key Points: 
  • Dr. Elzis recent research that will be presented next week at Cell Bio looks at why it works.
  • bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment.
  • OncoSelect Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in vitro to kill cancer cells without harm to normal cells.
  • Research and optimization of the Companys platform technologies are conducted in its laboratories at The University of Texas at San Antonio.

TIANGEN to Roll out a Stunning Automated Solution at Cell Bio 2022

Retrieved on: 
Wednesday, November 30, 2022
European Molecular Biology Organization, Thomas D. Pollard, Head, DC, ASCB, Cell biology, LTD, S16, Society, GM, Booth, EMBO, Research, Cell, Fine chemical, A4

It could be a stunning product for most molecular biologists and cell biologists to learn about.

Key Points: 
  • It could be a stunning product for most molecular biologists and cell biologists to learn about.
  • "Researchers spend lots of their time on the repetitive hands-on experiment, while there hasn't been an optimal automated nucleic acid extraction solution in the global life science market.
  • said Kefei Sun, the GM of TIANGEN, "TIANGEN develops the TGuide S16, that is groundbreaking to this field".
  • It has been committed to providing customers with a total solution from sample storage to nucleic acid extraction and detection.

RegeneRx Consultant to Receive Prestigious Award for Contributions in Field of Health

Retrieved on: 
Friday, February 11, 2022
Society, International Women's Media Foundation, Neurotrophic keratitis, Hildegard, Woman, WISE, Company, Federation, OTCQB, SEC, Form 10-K, Engineering, Annual report, Forward-looking statement, U.S. Securities and Exchange Commission, Animal, Security (finance), Female, Private Securities Litigation Reform Act, Royal College of Surgeons in Ireland, Consultant, Clinical trial, Herzfeld, Regeneration, Dry eye syndrome, National, Committee, National Institutes of Health, Institute, Jews, Thomas D. Pollard, Partnership, Risk, International Women's Day, NIH, Patent, Senior, Invention, Research, Eye, Cell biology, Royal college, Pharmaceutical industry, Dentistry, Health, EU, Science

Dr. Kleinman will be the first living Jewish female in the world to receive the prestigious Herzfeld Prize.

Key Points: 
  • Dr. Kleinman will be the first living Jewish female in the world to receive the prestigious Herzfeld Prize.
  • Her career and personal life emulate and mirror the historic achievements of Dr. Herzfeld both in health and the advancement of women in science.
  • Dr. Kleinman has published over 440 papers and been awarded ten patents, three of which have been successfully commercialized.
  • One of her inventions, Matrigel, is used worldwide and was among the top 15 National Institutes of Health (NIH) patents bearing royalties for many years.

bioAffinity Technologies Presents its Cancer Therapeutic Research at Joint ASCB-EMBO Meeting

Retrieved on: 
Monday, December 6, 2021
Research, Genetics, Clinical Trials, Biotechnology, Radiology, Health, Pharmaceutical, Science, Oncology, Research, EMBO, Lung, ASCB, Prostate, Cancer, LRP2, Technology, Sirna Therapeutics, Brain, Company, Diagnosis, Breast, University, Education, RNA interference, Laboratory, Therapy, COVID-19, Thomas D. Pollard, RNA, CD320, CST, Society, RNA transfection, Â, Medicine, Cell biology, Gene, European Molecular Biology Organization, Vaccine

bioAffinitys discovery of a fundamental vulnerability of cancer opens the way to new therapies that kill cancer without harm to normal tissue, Dr. Elzi said.

Key Points: 
  • bioAffinitys discovery of a fundamental vulnerability of cancer opens the way to new therapies that kill cancer without harm to normal tissue, Dr. Elzi said.
  • bioAffinity Technologies, Inc. ( www.bioaffinitytech.com ) is a privately held company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment.
  • The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells.
  • Research and optimization of its platform technology are conducted in bioAffinity Technologies laboratories at the University of Texas San Antonio.